Clinical trial
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With…
NCT00407303 · Gemin X, Industry · Completed
Key facts
| NCT number | NCT00407303 |
|---|---|
| Title | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| Official title | A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| Lead sponsor | Gemin X, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Mantle-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Obatoclax mesylate, Bortezomib |
| Enrollment | 24 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Dec 5, 2006 |
| Last update posted | Jul 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: